Department of Kinesiology, Faculty of Medicine, Laval University, Quebec, QC, Canada G1V 0A6.
Nutrition and Health Research Department, Nestlé Research Center, Lausanne, Switzerland.
Br J Nutr. 2014 Apr 28;111(8):1507-19. doi: 10.1017/S0007114513003875. Epub 2013 Dec 3.
The present study investigated the impact of a Lactobacillus rhamnosus CGMCC1.3724 (LPR) supplementation on weight loss and maintenance in obese men and women over 24 weeks. In a double-blind, placebo-controlled, randomised trial, each subject consumed two capsules per d of either a placebo or a LPR formulation (1.6 × 10(8) colony-forming units of LPR/capsule with oligofructose and inulin). Each group was submitted to moderate energy restriction for the first 12 weeks followed by 12 weeks of weight maintenance. Body weight and composition were measured at baseline, at week 12 and at week 24. The intention-to-treat analysis showed that after the first 12 weeks and after 24 weeks, mean weight loss was not significantly different between the LPR and placebo groups when all the subjects were considered. However, a significant treatment × sex interaction was observed. The mean weight loss in women in the LPR group was significantly higher than that in women in the placebo group (P = 0.02) after the first 12 weeks, whereas it was similar in men in the two groups (P= 0.53). Women in the LPR group continued to lose body weight and fat mass during the weight-maintenance period, whereas opposite changes were observed in the placebo group. Changes in body weight and fat mass during the weight-maintenance period were similar in men in both the groups. LPR-induced weight loss in women was associated not only with significant reductions in fat mass and circulating leptin concentrations but also with the relative abundance of bacteria of the Lachnospiraceae family in faeces. The present study shows that the Lactobacillus rhamnosus CGMCC1.3724 formulation helps obese women to achieve sustainable weight loss.
本研究旨在探讨干酪乳杆菌 CGMCC1.3724(LPR)补充剂对肥胖男女 24 周体重减轻和维持的影响。在一项双盲、安慰剂对照、随机试验中,每位受试者每天服用 2 粒安慰剂或 LPR 制剂(每粒胶囊含有 1.6×10(8)个 CFU 的 LPR、低聚果糖和菊粉)。两组均在前 12 周接受适度能量限制,然后进行 12 周的体重维持。在基线、第 12 周和第 24 周测量体重和体成分。意向治疗分析显示,在考虑所有受试者后,前 12 周和 24 周后,LPR 组和安慰剂组的平均体重减轻无显著差异。然而,观察到治疗×性别交互作用显著。在 LPR 组中,女性的平均体重减轻在前 12 周后明显高于安慰剂组(P=0.02),而两组男性的体重减轻相似(P=0.53)。在体重维持期间,LPR 组的女性继续减轻体重和体脂量,而安慰剂组则相反。两组男性在体重维持期间的体重和体脂量变化相似。女性的 LPR 诱导的体重减轻不仅与体脂量和循环瘦素浓度的显著降低有关,还与粪便中lachnospiraceae 家族细菌的相对丰度有关。本研究表明,干酪乳杆菌 CGMCC1.3724 配方有助于肥胖女性实现可持续的体重减轻。